EVLO SEC-arkivering - Evelo Biosciences, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1694665

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Evelo Biosciences, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

January 26, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
January 26, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38473 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in
January 26, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No.
January 26, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No.
January 26, 2024	POS AM	As filed with the Securities and Exchange Commission on January 26, 2024 As filed with the Securities and Exchange Commission on January 26, 2024 Registration No.
December 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
December 12, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a
December 4, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
December 1, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
November 21, 2023	EX-2.1	PLAN OF LIQUIDATION AND DISSOLUTION OF EVELO BIOSCIENCES, INC. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF EVELO BIOSCIENCES, INC. This Plan of Complete Liquidation and Dissolution (the “Plan”) is intended to constitute a plan of distribution under Section 281(b) of the General Corporation Law of the State of Delaware (“DGCL”) and accomplish the complete liquidation and dissolution of Evelo Biosciences, Inc., a Delaware corporation (such corporation or
November 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2023 EVELO BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
October 27, 2023	EX-10.1	FORBEARANCE AND SECOND AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT AND TWELFTH EXTENSION OF STANDSTILL AGREEMENT EX-10.1 Exhibit 10.1 FORBEARANCE AND SECOND AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT AND TWELFTH EXTENSION OF STANDSTILL AGREEMENT This FORBEARANCE AND SECOND AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT AND TWELFTH EXTENSION OF STANDSTILL AGREEMENT (this “Agreement”), dated as of October 26, 2023, is entered into by and among Evelo Biosciences, Inc., a Delaware corporation (“Borrower”
October 27, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
October 17, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
August 21, 2023	EX-10.1	August 18, 2023 Exhibit 10.1 August 18, 2023 Balkrishan (Simba) Gill, Ph.D. RE: Bonus Dear Simba, Evelo Biosciences, Inc. (the “Company” or “Evelo”) is pleased to inform you that you are eligible to earn a special, one-time cash bonus (the “Bonus”) in the amount of $300,000, pursuant to the terms and conditions set forth in this letter agreement. Subject to the terms of this letter agreement, the Bonus will be pa
August 21, 2023	424B3	13,189,836 Shares Common Stock Offered by the Selling Securityholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-273869 PROSPECTUS 13,189,836 Shares Common Stock Offered by the Selling Securityholders The selling securityholders may offer and sell up to 13,189,836 shares in the aggregate of common stock identified above from time to time in one or more offerings. This prospectus provides you with a general description of the common st
August 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 EVELO BIOSCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizat
August 15, 2023	CORRESP	Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, Massachusetts 02139 Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, Massachusetts 02139 August 15, 2023 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: EVELO BIOSCIENCES, INC. Registration Statement on Form S-3 (Registration No. 333-273869) Ladies and Gentlemen: In accordance with Rule 461 under the Securities
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 14, 2023	EX-99.1	Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructur EX 99.1 Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., August 14, 2023 – Evelo Biosciences, Inc. (Nasdaq: E
August 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Evelo Biosciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizat
August 10, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 Form Type Evelo Biosciences, Inc.
August 10, 2023	S-3	As filed with the Securities and Exchange Commission on August 10, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 10, 2023 Registration No.
July 21, 2023	SC 13G	US2997342025 / Evelo Biosciences Inc / HarbourVest Partners L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734202 (CUSIP Number) July 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
July 21, 2023	EX-99.1	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree that the Statement on Schedule 13G to which this Exhibit is attached is filed on behalf of each of them. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached. Each o
July 21, 2023	SC 13G	US2997342025 / Evelo Biosciences Inc / Horizon Technology Finance Corp - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 20, 2023	EX-10.1	Sublease Termination and Surrender Agreement, dated as of July 14, 2023, by and between Evelo Biosciences, Inc. and Bio-Rad Laboratories, Inc. Exhibit 10.1 SUBLEASE TERMINATION AND SURRENDER AGREEMENT This SUBLEASE TERMINATION AND SURRENDER AGREEMENT (this “Agreement”) is made as of July 10, 2023, by and between Bio-Rad Laboratories, Inc., a Delaware corporation, having its principle place of business at 1000 Alfred Nobel Drive, Hercules, California 94547 (”Sublandlord”), and Evelo Biosciences, Inc., a Delaware corporation, having an off
July 13, 2023	SC 13D/A	US2997342025 / Evelo Biosciences Inc / Flagship Ventures Fund V, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734202 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering Inc. 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Nam
July 12, 2023	EX-99.1	Evelo Biosciences Closes $25.5 Million Private Placement Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors Exhibit 99.1 Evelo Biosciences Closes $25.5 Million Private Placement Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) - Evelo Biosciences, Inc. (Nasdaq:EVLO) (the “Company” or “Evelo”), a clinical stage biotechnology company developing a novel platfor
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 12, 2023	EX-10.1	Registration Rights Agreement, dated as of July 11, 2023, by and among Evelo Biosciences, Inc. and the Investors named therein. Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of July 11, 2023 by and among Evelo Biosciences, Inc., a Delaware corporation (the “Company”), and the “Investors” named in the Securities Purchase Agreement, dated as of July 7, 2023, between the Company and each of the Investors identified on Schedule I attached thereto (t
July 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2023 EVELO BIOSCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
July 10, 2023	EX-99.1	Evelo Biosciences Announces $25.5 Million Private Placement Exhibit 99.1 Evelo Biosciences Announces $25.5 Million Private Placement CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) - Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreemen
July 10, 2023	EX-10.2	Waiver and Amendment to Venture Loan and Security Agreement and Eleventh Extension of Standstill Agreement, dated as of July 7, 2023, by and among Evelo Biosciences, Inc., Horizon Technology Finance Corporation, as Collateral Agent, and the Lenders thereto. Exhibit 10.2 WAIVER AND AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT AND ELEVENTH EXTENSION OF STANDSTILL AGREEMENT This WAIVER AND AMENDMENT TO VENTURE LOAN AND SECURITY AGREEMENT AND ELEVENTH EXTENSION OF STANDSTILL AGREEMENT (this “Agreement”), dated as of July 7, 2023, is entered into by and among Evelo Biosciences, Inc., a Delaware corporation (“Borrower”), Horizon Credit II LLC, a Delawa
July 10, 2023	EX-10.1	Securities Purchase Agreement, dated as of July 7, 2023, by and among Evelo Biosciences, Inc. and the Investors named therein. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 7, 2023, between Evelo Biosciences, Inc., a Delaware corporation (the “Company”), and each of the investors identified on Schedule I attached hereto (each, including its successors and assigns, an “Investor” and collectively the “Investors”). RECITALS A.The Company and each Investor
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 29, 2023	EX-3.1	Certificate of Amendment to Restated Certificate of Incorporation of Evelo Biosciences, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF EVELO BIOSCIENCES, INC. Evelo Biosciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: That the Board of Directors of the Corporation duly adopted resolutions recommending and declarin
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2023 EVELO BIOSCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 8, 2023	EX-10.1	Evelo Biosciences, Inc. 2018 Incentive Award Plan, as amended and restated Exhibit 10.1 EVELO BIOSCIENCES, INC. 2018 INCENTIVE AWARD PLAN (As Amended & Restated) ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article
May 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 EVELO BIOSCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2023 EVELO BIOSCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2023 EVELO BIOSCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 1, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
April 18, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 EVELO BIOSCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
March 16, 2023	EX-10.13	Severance Agreement, dated February 13, 2023, by and between Evelo Biosciences, Inc. and Jonathan Zung Ex 10.13 620 Memorial Drive ● Cambridge, MA 02139 February 13, 2023 Personal and Confidential Jonathan Zung 2900 Spaldwick Ct Raleigh, NC 27613 Separation Agreement and Voluntary Release Dear Jonathan: The purpose of this letter agreement (“Agreement”) is to confirm the terms of your separation of employment from Evelo Biosciences, Inc. (“Evelo” or the “Company”, as defined below).1 The Transition
March 16, 2023	EX-10.16	Letter Agreement, dated February 1, 2023, by and between Evelo Biosciences, Inc. and Marella Thorell EX 10.16 February 1, 2023 Marella Thorell RE: Retention Bonus Dear Marella, Evelo Biosciences, Inc. (the “Company” or “Evelo”) is pleased to inform you that you are eligible to earn a special, one-time retention bonus (the “Retention Bonus”) in the amount of $150,000, pursuant to the terms and conditions set forth in this letter agreement. Subject to the terms of this letter agreement, the Retenti
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Evelo Biosciences, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
March 16, 2023	10-K	Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number
March 16, 2023	EX-99.1	Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights EX 99.1 Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights CAMBRIDGE, Mass., March 16, 2023 – Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financ
February 21, 2023	SC 13D/A	EVLO / Evelo Biosciences Inc / Dnca Finance - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) EVELO BIOSCIENCES, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 299734103 (CUSIP Number) DNCA FINANCE S.C.S 19, Place Vendôme 75001 Paris, FRANCE To : Mr. Rodrigo LOZANO (Name, Address and Telephone Number of Person Authorized to Rec
February 17, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
February 14, 2023	SC 13G/A	EVLO / Evelo Biosciences Inc / HarbourVest Partners L.P. - SC 13G/A Passive Investment SC 13G/A 1 d430555dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropr
February 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
February 2, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2023 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
February 2, 2023	SC 13G/A	EVLO / Evelo Biosciences Inc / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 299734103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 2, 2023	EX-99.1	In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the EX-99.1 2 ex991.htm EX-99.1 In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 EVELO BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
December 16, 2022	EX-4.1	Form of Warrant to Purchase Common Stock, dated as of December 15, 2022, issued by Evelo Biosciences, Inc. to Horizon Technology Finance Corporation, together with a schedule of warrantholders EX-4.1 Exhibit 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Number of Shares Loan Name Horizon Technology Finance Corporation 103,092 A Horizon Technology Finance Corporation 154,639 B Horizon Technology Finance Corporation 61,855 C Hor
December 16, 2022	EX-10.1	Loan and Security Agreement by and among Evelo Biosciences, Inc. and Horizon Technology Finance Corporation, dated December 15, 2022 EX-10.1 Exhibit 10.1 VENTURE LOAN AND SECURITY AGREEMENT Dated as of December 15, 2022 (the “Effective Date”) by and among HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation 312 Farmington Avenue Farmington, CT 06032 as a Lender and Collateral Agent And EVELO BIOSCIENCES, INC., a Delaware corporation 620 Memorial Drive, 5th Floor Cambridge, MA 02138 as Borrower Loan A Commitment Amount
November 21, 2022	SC 13D/A	EVLO / Evelo Biosciences Inc / Dnca Finance - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) EVELO BIOSCIENCES, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 299734103 (CUSIP Number) DNCA FINANCE S.C.S 19, Place Vendôme 75001 Paris, FRANCE To : Mr. Rodrigo LOZANO (Name, Address and Telephone Number of Person Authorized to Rec
November 15, 2022	EX-99.1	Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights - Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights - Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle product candidate EDP2939 in psoriasis anticipated in 2H 2023 ? - Continuing to advance regulatory discussions for registration trials for EDP1815 in psoriasis - CAMBRIDGE, Mass.
November 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
November 14, 2022	EX-10.1	, by and between Evelo Biosciences, Inc. and 620 Memorial Drive, Cambridge, MA 02139 June 30, 2022 Marella Thorell ***@gmail.com Re: Employment by Evelo Biosciences, Inc. Dear Marella, Evelo Biosciences, Inc. is pleased to confirm its offer to employ you as Chief Financial Officer or such other capacity as may be mutually agreed upon by the Company and you from time to time. Your effective date of hire as a regular, full-time employee is ant
November 14, 2022	EX-4.1	Amended and Restated Warrant to Purchase Common Stock, dated as of November 14, 2022, issued by Evelo Biosciences, Inc. to K2 HealthVentures Equity Trust LLC THIS AMENDED AND RESTATED WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.
November 14, 2022	EX-10.2	Modification Letter, dated as of November 14, 2022, to the Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent for such lenders, and Ankura Trust Company, LLC, as collateral agent for such lenders, dated July 19, 2019, as amended November 14, 2022 Evelo Biosciences, Inc. 620 Memorial Drive, 5th Floor Cambridge, MA 02139 Attention: Marella Thorell Re: Waiver of Specified Defaults and Modification of Terms Ladies and Gentlemen: Reference is made to that certain Loan and Security Agreement, dated as of July 19, 2019 (as amended, restated, supplemented or otherwise modified, from time to time, the ?Agreement?), among EVELO BIO
August 23, 2022	SC 13D/A	EVLO / Evelo Biosciences Inc / Dnca Finance - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) EVELO BIOSCIENCES, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 299734103 (CUSIP Number) DNCA FINANCE S.C.S 19, Place Vend?me 75001 Paris, FRANCE To : Mr. Rodrigo LOZANO (Name, Address and Telephone Number of Person Authorized to Rec
August 11, 2022	EX-10.2	between Evelo Biosciences, Inc. and 620 Memorial Drive, Cambridge, MA 02139 December 14, 2020 Jonathan Zung Re: Employment by Evelo Biosciences, Inc.
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2022 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizat
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu
August 11, 2022	EX-99.1	Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights – Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end– – Two Phase 2 clinical read-outs with EDP1815 in atopic dermat Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights – Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end– – Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023– – Phase 2 data for EDP2939 in psoriasis expected in 2H 2023– – Management will host conference call at 7:30 a.
August 11, 2022	EX-10.3	2021, by and between Evelo Biosciences, Inc. and 620 Memorial Drive, Cambridge, MA 02139 March 12, 2021 Luca Scavo Re: Employment by Evelo Biosciences, Inc.
July 18, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 1, 2022	424B5	Up to $75,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424b(5) Registration No. 333-259005 PROSPECTUS SUPPLEMENT (To Prospectus dated August 30, 2021) Up to $75,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated July 1, 2022, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales ag
July 1, 2022	EX-1.1	Sales Agreement, dated July 1, 2022, between Evelo Biosciences, Inc. and Cowen and Company, LLC. EX-1.1 2 atmsalesagreementconformed.htm EX-1.1 EXHIBIT 1.1 EVELO BIOSCIENCES, INC. $75,000,000 COMMON STOCK SALES AGREEMENT July 1, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Evelo Biosciences, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1.Issuance and Sale of Shares. The Company a
July 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 9, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 1, 2022	SC 13D/A	EVLO / Evelo Biosciences Inc / Flagship Ventures Fund V, L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734103 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering Inc. 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Nam
June 1, 2022	EX-99.1	JOINT FILING AGREEMENT CUSIP No. 299734103 Exhibit 99.1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: June
May 25, 2022	EX-1.1	Form of Securities Purchase Agreement, dated May 25, 2022, by and among the Company and the several Purchasers named therein. EX-1.1 2 d319158dex11.htm EX-1.1 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 25, 2022, between Evelo Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje
May 25, 2022	424B5	54,246,358 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259005 P R O S P E C T U S S U P P L E M E N T 54,246,358 Shares Common Stock We are offering 54,246,358 shares of our common stock to certain investors, or the Investors, pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with the Investors. Our shares trade on The Nasda
May 25, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 47-5594527 (State or other jurisdiction of incorporation or organization
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File N
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2022 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
May 12, 2022	EX-99.1	Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights CAMBRIDGE, Mass.
April 26, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) DEF 14A 1 evelo-proxystatementfor202.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident
April 26, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
April 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
April 5, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
March 24, 2022	EX-10.17	Patent License Agreement between Mayo Foundation for Medical Education and Research and Evelo Biosciences, Inc., dated August 6, 2017, as amended January 19, 2018 and further amended November 15, 2021 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10).
March 24, 2022	EX-10.21	Amendment No. 1 to Clinical Master Services Agreement between Evelo Biosciences, Inc. and Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany, dated February 8, 2022 Amendment No. 1 to Development and Clinical Master Services Agreement This Amendment No. 1 (this ?Amendment?), dated as of February 8, 2022 (?Amendment Effective Date?), between Evelo Biosciences, Inc. (the ?Client?) and Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany (the ?Cambrex?) amends that certain Development and Clinical Master Services Agreement, dated December 17, 2020, between the Clien
March 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38473 Evelo Bioscie
March 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
March 24, 2022	EX-10.5	Evelo Biosciences, Inc. Non-Employee Director Compensation Program, as amended, effective April 1, 2022 EVELO BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Evelo Biosciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?), as amended by the Board effective April 1, 2022 (the ?Effective Date?). The cash and equity compensation
March 24, 2022	EX-99.1	Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights –Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 – –Positive Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights ?Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022 ? ?Positive data reported on faster release capsule? ?Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout? ?Management to host conference call at 8:30 a.
February 28, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
February 14, 2022	EX-99.1	In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio
February 14, 2022	SC 13G/A	EVLO / Evelo Biosciences Inc / CREDIT SUISSE AG/ - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 299734103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 7, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2022 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
January 4, 2022	EX-10.1	Employment Agreement of Mark Bodmer by and between Evelo Biosciences (UK) Limited and Mark Bodmer, dated December 31, 2021 Mark W. Bodmer, Ph.D. XXXXXX XXXXXX XXXXXX 31 December 2021 Dear Mark, Your terms of employment Further to our recent discussions. This letter sets out the terms of your employment as required by section 1 of the Employment Rights Act 1996. It should be read in tandem with the information that is set out in our Staff Handbook which accompanies this letter. 1.Start of your employment with Evelo Bio
January 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
December 28, 2021	SC 13D	EVLO / Evelo Biosciences Inc / Dnca Finance - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) EVELO BIOSCIENCES, INC. (Name of Issuer) Common Shares (Title of Class of Securities) 299734103 (CUSIP Number) DNCA FINANCE S.C.S 19, Place Vend?me 75001 Paris, FRANCE To : Mr. Rodrigo LOZANO (Name, Address and Telephone Number of Person Authorized to Rece
December 22, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
October 29, 2021	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period fro
October 28, 2021	EX-99.1	Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights –Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies– –Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to b Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights ?Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies? ?Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021? ?Preclinical data support development of EDP1867 in neuroinflammatory diseases? ?Management to host conference call at 8:30 a.
October 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
October 28, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission Fi
September 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organi
September 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organi
September 28, 2021	EX-99.1	Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private stockholders have the ability to control or significantly influence our business; costs and Securities Litigation Reform Act of 1995. All stateme Exhibit 99.1 Topline Results for Phase 2 Study of EDP1815 in Mild and Moderate Psoriasis September 27, 2021 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private stockholders have the ability to control or significantly influence our business; costs and Securities Litigation Reform Act of 1995. All statements contained in this presentation resourc
September 28, 2021	EX-99.2	Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease –Clinically and statistically significant improvement in PASI Exhibit 99.2 Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX?, to Treat Systemic Inflammatory Disease ?Clinically and statistically significant improvement in PASI-50 score achieved? ?EDP1815 safety and tolerability data comparable to placebo in study? ?EDP1815 advancing towards registration studies
September 7, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
August 26, 2021	CORRESP	Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, Massachusetts 02139 Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, Massachusetts 02139 August 26, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: EVELO BIOSCIENCES, INC. Registration Statement on Form S-3 (Registration No. 333-259005) Ladies and Gentlemen: In accordance with Rule 461 under the Securities
August 23, 2021	S-3	As filed with the Securities and Exchange Commission on August 23, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 23, 2021 Registration No.
July 29, 2021	EX-99.1	Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights –EDP1815 Phase 2b data in psoriasis expected in 3Q 2021– –Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated i Exhibit 99.1 Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights ?EDP1815 Phase 2b data in psoriasis expected in 3Q 2021? ?Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021? ?Strengthened leadership team with appointment of Mark Plinio as Chief Commercial Officer? ?Multiple clinical data readouts ex
July 29, 2021	EX-10.3	Evelo Biosciences, Inc. Non-Employee Director Compensation Program, as amended June 9, 2021 Exhibit 10.3 Evelo Biosciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of Evelo Biosciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?), as amended by the Board effective June 9, 2021 (the ?Effective Date?). The cash and equity
July 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu
June 17, 2021	EX-4.1	Warrant to Purchase Common Stock, dated as of June 16, 2021, issued by Evelo Biosciences, Inc. to K2 HealthVentures Equity Trust LLC Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR UNTIL SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS
June 17, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 17, 2021	EX-10.1	Fourth Amendment, dated as of June 16, 2021, to the Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent for such lenders, and Ankura Trust Company, LLC, as collateral agent for such lenders, dated July 19, 2019, as amended Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is dated as of June 16, 2021, by and among EVELO BIOSCIENCES, INC., a Delaware corporation (?Borrower Representative?), the undersigned lenders, constituting the Required Lenders, and K2 HEALTHVENTURES LLC, as administrative agent for Lenders (in such capacity, and t
June 10, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 1, 2021	S-8	As filed with the Securities and Exchange Commission on June 1, 2021 As filed with the Securities and Exchange Commission on June 1, 2021 Registration No.
June 1, 2021	EX-99.1	Evelo Biosciences, Inc. 2021 Employment Inducement Award Plan, and U.K. sub-plan and forms of award agreements thereunder Exhibit 99.1 EVELO BIOSCIENCES, INC. 2021 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGI
April 29, 2021	EX-10.3	Amendment dated April 9, 2021 to Letter Agreement between Evelo Biosciences, Inc. and David R. Epstein Exhibit 10.3 April 9, 2021 Mr. David R. Epstein [*] [*] Re: Amendment No. 2 to Letter Agreement Dear David, Reference is made to my letter dated as of September 16, 2019 addressed to you concerning your compensation for serving as the Chair of the Board of Directors of Evelo Biosciences, Inc. (as previously amended, the ?Letter Agreement?). This letter memorializes our recent discussion concer
April 29, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001
April 29, 2021	EX-99.1	Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights –Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with Exhibit 99.1 Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights ?Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting? ?Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors? ?Announced strategic collaboration with
April 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
April 29, 2021	EX-10.2	Amendment No. 2 to Consulting Agreement dated April 9, 2021 between Evelo Biosciences, Inc. and David R. Epstein Exhibit 10.2 Evelo Biosciences, Inc. Amendment No. 2 to Consulting Agreement This Amendment to that certain Consulting Agreement dated as of September 16, 2019 (as previously amended, the ?Agreement?) is entered into by and between Evelo Biosciences, Inc., a Delaware corporation with a place of business located at 620 Memorial Drive, Cambridge, Massachusetts 02139, USA (the ?Company?), and David E
April 26, 2021	DEF 14A	Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted
April 26, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
April 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
March 23, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
March 23, 2021	EX-1.1	Commercialization and License Agreement dated March 17, 2021 by and between Evelo Biosciences, Inc. and Meddist Company Limited Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
March 18, 2021	EX-3.1	Amended and Restated Bylaws of Evelo Biosciences, Inc. Exhibit 5.03 AMENDED AND RESTATED BYLAWS OF EVELO BIOSCIENCES, INC. (a Delaware corporation) Effective March 17, 2021 TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 AD
March 18, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
March 9, 2021	EX-10.17	Development and Clinical Master Services Agreement between Evelo Biosciences, Inc. and Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany dated December 17, 2020 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed Exhibit 10.
March 9, 2021	EX-99.1	Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1 Exhibit 99.1 Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatit
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
March 9, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES For the Fiscal Year Ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38473 Evelo Bioscie
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSI SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 12, 2021	EX-99.1	In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolutio
February 12, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 299734103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 4, 2021	EX-99.2	LOCK-UP AGREEMENT EX-99.2 Exhibit 2 LOCK-UP AGREEMENT January 28, 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Re: Evelo Biosciences, Inc.—Public Offerin
February 4, 2021	EX-99.1	JOINT FILING AGREEMENT EX-99.1 CUSIP No. 299734103 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated:
February 4, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSI SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734103 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering Inc. 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Nam
February 2, 2021	EX-1.1	Underwriting Agreement, dated January 28, 2021, by and among the Company and Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein. EX-1.1 Exhibit 1.1 Execution Version 4,500,000 Shares EVELO BIOSCIENCES, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT January 28, 2021 Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladi
February 2, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 28, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 47-5594527 (State or other jurisdiction of incorporation or organiza
January 29, 2021	424B5	4,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231911 P R O S P E C T U S S U P P L E M E N T (to Prospectus dated June 6, 2019) 4,500,000 Shares Common Stock We are offering 4,500,000 shares of our common stock. Our shares trade on The Nasdaq Global Select Market under the symbol “EVLO.” On January 28, 2021, the last sale price of our shares as reported on The Nasda
January 28, 2021	424B5	Subject to Completion Preliminary Prospectus Supplement dated January 28, 2021 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231911 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
January 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
January 20, 2021	EX-99.1	Complete Phase 1b Dataset: EDP1815 in Atopic Dermatitis January 20, 2021 Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in th corporateslidepresentant Complete Phase 1b Dataset: EDP1815 in Atopic Dermatitis January 20, 2021 Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
January 20, 2021	8-K	Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 20, 2021 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
December 17, 2020	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
December 9, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
October 30, 2020	EX-10.2	Letter Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended Exhibit 10.2 September 16, 2019 Mr. David R. Epstein [***] RE: Compensation for Services as Chairman of Board of Directors Dear David, Thank you for agreeing to serve as the Chairman (the "Chairman") of the Board of Directors (the "Board") of Evelo Biosciences, Inc. (the "Company"). This letter memorializes our recent discussion concerning your compensation for serving as the Chairman. The compens
October 30, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
October 30, 2020	EX-10.3	Consulting Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended Exhibit 10.3 Evelo Biosciences, Inc. Consulting Agreement This Consulting Agreement (the "Agreement"), made as of September 16, 2019, is entered into by Evelo Biosciences, Inc., a Delaware corporation with offices at 620 Memorial Drive, Cambridge, Massachusetts 02139 (the "Company"), and David R. Epstein, an individual residing at [***] (the "Consultant"). WHEREAS, the Company and the Consultant d
October 29, 2020	EX-99.1	Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights -- Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis -- -- Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast Exhibit 99.1 Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights - Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis - - Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months - -Advancing newly discovered microbial extracellular vesicles as next-generation SINTAX-based medicine
October 29, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
July 31, 2020	EX-10.2	Third Amendment to Loan and Security Agreement dated as of July 8, 2020 by and among Evelo Biosciences, Inc., the lenders party thereto and K2 HealthVentures LLC, as administrative agent for such lenders Exhibit 10.2 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. July 8, 2020 Evelo Biosciences, Inc. 620 Memorial Drive, Suite 500 West Cambridge, MA 02139 Attention: Daniel Char and Jonathan Poole Re: Third Amendment to Loan and Security Agreement Ladies and Gentlemen: Reference
July 31, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
July 30, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 30, 2020	EX-99.1	Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights – FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 – –Achieved regulatory and ethics authorization for Phas Exhibit 99.1 Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights – FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 – –Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in moderate psoriasis in the U.S., UK, and EU; trial initiation expected in 3Q 2020 with interim data
July 1, 2020	EX-99.2	LOCK-UP AGREEMENT EX-99.2 Exhibit 2 LOCK-UP AGREEMENT , 2020 Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Re: Evelo Biosciences, Inc.—Public Offering Ladies a
July 1, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d936763dex991.htm EX-99.1 CUSIP No. 299734103 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities E
July 1, 2020	SC 13D/A	EVLO / Evelo Biosciences, Inc. / Flagship Ventures Fund V, L.p. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 299734103 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering Inc. 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Nam
June 29, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 29, 2020	EX-1.1	Underwriting Agreement, dated June 24, 2020, by and among the Company and Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein. Exhibit 1.1 EXECUTION VERSION 12,000,000 Shares EVELO BIOSCIENCES, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT June 24, 2020 \|US-DOCS\113923238.3 ACTIVE/102311404.7 \|US-DOCS\116657701.2 Evelo - Underwriting Agreement (2020 Follow-on)\|\| Morgan Stanley & Co. LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway
June 25, 2020	424B5	12,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231911 P R O S P E C T U S S U P P L E M E N T (to Prospectus dated June 6, 2019) 12,000,000 Shares Common Stock We are offering 12,000,000 shares of our common stock. Our shares trade on The Nasdaq Global Select Market under the symbol “EVLO.” On June 24, 2020, the last sale price of our shares as reported on The Nasdaq
June 24, 2020	424B5	$40,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231911 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
June 18, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
May 18, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
May 18, 2020	EX-10.1	Second Amendment to Loan and Security Agreement dated as of May 15, 2020 by and among Evelo Biosciences, Inc., the lenders party thereto and K2 HealthVentures LLC, as administrative agent for such lenders. k2secondamendmentevelo5 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of May 15, 2020, by and among EVELO BIOSCIENCES, INC.
May 11, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001
May 11, 2020	EX-99.1	Evelo Biosciences Reports First Quarter Financial Results and Business Highlights –Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020– – Selected enteric capsule form Exhibit 99.1 Evelo Biosciences Reports First Quarter Financial Results and Business Highlights –Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020– – Selected enteric capsule formulation of EDP1815 for Phase 2 dose ranging trial in psoriasis; trial initiation now expected in 3Q 2020, with interim data in mid-2021–
May 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
April 27, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
April 27, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
April 27, 2020	DEF 14A	definitive proxy statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
April 27, 2020	EX-99.1	April 27, 2020 Exhibit 99.1 April 27, 2020 Dear Stockholders, Our vision and strategy. Our vision has consistently been to develop a new profile of medicines that are broadly applicable, effective, safe, convenient to take and affordable. This profile is enabled by the newly uncovered biology of the small intestinal axis, SINTAX™. SINTAX is the network of connections between the small intestine and the rest of t
February 28, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
February 14, 2020	EX-10.4	Non-Employee Director Compensation Program, as amended Exhibit 10.4 Evelo Biosciences, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Evelo Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective December 4, 2019 (the “Effective Date”). The cash and equ
February 14, 2020	EX-10.3	2018 Employee Stock Purchase Plan, as amended Exhibit 10.3 EVELO BIOSCIENCES, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective November 26, 2019) ARTICLE I. PURPOSE The purposes of this Evelo Biosciences, Inc. 2018 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Evelo Biosciences, Inc., a Delaware corporation (the “Company”), and its Des
February 14, 2020	EX-10.5	Executive Severance Plan, as amended Exhibit 10.5 EVELO BIOSCIENCES, INC. EXECUTIVE SEVERANCE PLAN I. PURPOSE The purpose of this Evelo Biosciences, Inc. Executive Severance Plan (the “Plan”) is to encourage certain employees of Evelo Biosciences, Inc. (the “Company”) to remain in the employ of the Company by providing severance protections to such employees in the event their employment is terminated under the circumstances describe
February 14, 2020	EX-21.1	Subsidiaries of Evelo Biosciences, Inc. Exhibit 21.1 SUBSIDIARIES OF EVELO BIOSCIENCES, INC. Legal Name of Subsidiary Jurisdiction of Organization Evelo Biosciences (UK) Limited England and Wales Evelo Biosciences Security Corporation Massachusetts
February 14, 2020	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES For the Fiscal Year Ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38473 Evelo Bioscie
February 14, 2020	EX-4.3	Description of Capital Stock Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Evelo Biosciences, Inc. (the “Company,” “we,” “us” and “our”) is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our restated certificate of incorporation and ou
February 13, 2020	EX-99.1	Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights —Strong 2019 marked by clinical data that validates platform— —Lead inflammation candidate EDP1815 showed positive clinical data across two separate Exhibit 99.1 Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights —Strong 2019 marked by clinical data that validates platform— —Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts— —EDP1815 Phase 2 study initiation expected in Q2 2020— —Multiple clinical readouts across inflammation and oncology portfolio e
February 13, 2020	EX-99.2	Fourth Quarter and Full Year 2019 Financial Results and Business Highlights February 13, 2020 Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All state q42019earningsdeckvf Fourth Quarter and Full Year 2019 Financial Results and Business Highlights February 13, 2020 Legal disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
February 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2020 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
December 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 4, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
November 5, 2019	EX-10.4	Amendment No. 1 to Exclusivity and Commitment Agreement between Biose and Evelo Biosciences, Inc., dated August 1, 2019 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
November 5, 2019	10-Q	EVLO / Evelo Biosciences, Inc. 10-Q - Quarterly Report - EVELO 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
November 5, 2019	EX-99.2	Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial --EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-- --Reduction in Mean Lesion Severity Sco Exhibit 99.2 Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial -EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo- -Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent with Low Dose Cohort- - Dose Response Trends Observed in LSS and PASI at Day 42- -Phase 2 Study Initiation Ex
November 5, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
November 5, 2019	EX-99.3	New Therapeutic Modality Supported by Positive Interim Clinical Data EDP1815 Advancing into Phase 2 November 5, 2019 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform edp18155xxdataxpresenta New Therapeutic Modality Supported by Positive Interim Clinical Data EDP1815 Advancing into Phase 2 November 5, 2019 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
November 5, 2019	EX-99.1	Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results --EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-- --Reduction in Mean Lesion Sever EX-99.1 2 exhibit9912019q3.htm EXHIBIT 99.1 Exhibit 99.1 Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results -EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo- -Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent between High and Low Dose Cohort- - Dose Response Trends O
September 18, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organi
September 18, 2019	EX-10.2	Consulting Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended Exhibit 10.2 Evelo Biosciences, Inc. Consulting Agreement This Consulting Agreement (the "Agreement"), made as of September 16, 2019, is entered into by Evelo Biosciences, Inc., a Delaware corporation with offices at 620 Memorial Drive, Cambridge, Massachusetts 02139 (the "Company"), and David R. Epstein, an individual residing at [***] (the "Consultant"). WHEREAS, the Company and the Consultant d
September 18, 2019	EX-10.1	Letter Agreement, dated September 16, 2019, between Evelo Biosciences, Inc. and David R. Epstein, as amended Exhibit 10.1 September 16, 2019 Mr. David R. Epstein [***] RE: Compensation for Services as Chairman of Board of Directors Dear David, Thank you for agreeing to serve as the Chairman (the "Chairman") of the Board of Directors (the "Board") of Evelo Biosciences, Inc. (the "Company"). This letter memorializes our recent discussion concerning your compensation for serving as the Chairman. The compens
August 6, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
August 6, 2019	EX-99.3	Broad Platform Opportunity and New Therapeutic Modality Supported by Positive Interim Clinical Data EDP1815 Advancing to Phase 2 August 6, 2019 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private S edp1815datapresentationv Broad Platform Opportunity and New Therapeutic Modality Supported by Positive Interim Clinical Data EDP1815 Advancing to Phase 2 August 6, 2019 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
August 6, 2019	EX-99.2	Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial -EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo- -Patients Dosed with EDP1815 Showed a Reduction Exhibit 99.2 Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial -EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo- -Patients Dosed with EDP1815 Showed a Reduction in Mean Lesion Severity Score vs. Placebo- -Reductions Observed in Cellular Histological and Blood Immune Cell Biomarkers Consistent wit
August 6, 2019	EX-99.1	Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results -EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo- -Clinical Response Observed Consistent w Exhibit 99.1 Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results -EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo- -Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell Biomarkers in Psoriasis Patients at Low Dose of EDP1815- -EDP1815 Phase 2 I
August 6, 2019	EX-10.1	Loan and Security Agreement between Pacific Western Bank and Evelo Biosciences, Inc., dated August 15, 2016, as amended on June 14, 2017, August 18, 2017, February 7, 2018, March 14, 2018 and April 18, 2019. Exhibit 10.1 EVELO BIOSCIENCES, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the "Agreement") is entered into as of August 15, 2016, by and between PACIFIC WESTERN BANK, a California state chartered bank ("Bank") and EVELO BIOSCIENCES, INC., a Delaware corporation ("Borrower"). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend c
August 6, 2019	EX-10.3	Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent for such lenders, and Ankura Trust Company, LLC, as collateral agent for such lenders, dated July 19, 2019, as amended Exhibit 10.3 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of July 19, 2019 (the “Closing Date”) is entered into among EVELO BIOSCIENCES, INC., a Delaware corporation (“Borrower Representative”), and each other Person party hereto as a borrower from time to time (collectively, “Bo
August 6, 2019	10-Q	EVLO / Evelo Biosciences, Inc. 10-Q - Quarterly Report - EVELO 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
August 6, 2019	EX-10.4	Collaboration Agreement between Evelo Biosciences, Inc. and Sacco S.r.l. dated July 9, 2019 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
July 24, 2019	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
July 24, 2019	EX-10.1	Loan and Security Agreement by and among Evelo Biosciences, Inc. and the other borrowers party thereto, the lenders party thereto, K2 HealthVentures LLC, as administrative agent for such lenders, and Ankura Trust Company, LLC, as collateral agent for such lenders. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of July 19, 2019 (the “Closing Date”) is entered into among EVELO BIOSCIENCES, INC.
July 11, 2019	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 14, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 evelo8-kitem5026122019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdi
June 13, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizatio
June 7, 2019	424B5	Up to $50,000,000 Common Stock Filed Pursuant to Rule 424b(5) Registration No. 333-231911 PROSPECTUS SUPPLEMENT Up to $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated June 3, 2019, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreement, under this prospectus supplement we may offer a
June 4, 2019	CORRESP	EVLO / Evelo Biosciences, Inc. CORRESP - - Evelo Biosciences, Inc. 620 Memorial Drive Cambridge, Massachusetts 02139 June 4, 2019 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Re: EVELO BIOSCIENCES, INC. Registration Statement on Form S-3 (Registration No. 333-231911) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Ac
June 3, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization
June 3, 2019	S-3	EVLO / Evelo Biosciences, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on June 3, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Evelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 46-5594527 (State or other jurisdiction of incorporation or organization) (I.R.S. E
June 3, 2019	EX-1.2	Sales Agreement, dated as of June 3, 2019, between Evelo Biosciences, Inc. and Cowen and Company, LLC (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 (Reg. No. 333-231911) filed on June 3, 2019) Exhibit 1.2 EVELO BIOSCIENCES, INC. $50,000,000 COMMON STOCK SALES AGREEMENT June 3, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Evelo Biosciences, Inc. (the "Company"), confirms its agreement (this "Agreement") with Cowen and Company, LLC ("Cowen"), as follows: 1.Issuance and Sale of Shares. The Company agrees that, from time to time during the term o
May 3, 2019	EX-10.1	Loan and Security Agreement between Pacific Western Bank and Evelo Biosciences, Inc., dated August 15, 2016, as amended on June 14, 2017, August 18, 2017, February 7, 2018, March 14, 2018 and April 18, 2019. Exhibit 10.1 EVELO BIOSCIENCES, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the "Agreement") is entered into as of August 15, 2016, by and between PACIFIC WESTERN BANK, a California state chartered bank ("Bank") and EVELO BIOSCIENCES, INC., a Delaware corporation ("Borrower"). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend c
May 3, 2019	10-Q	Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001
May 2, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organization)
May 2, 2019	EX-99.1	Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights -- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold: Plan to Introduce New Formulation into Ongoing Cli Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights - Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold: Plan to Introduce New Formulation into Ongoing Clinical Trials in Second Half of 2019 - - Initial Clinical Data for EDP1066 Expected Early in Third Quarter of 2019 - - On Track to Deliver 10 Clinical Readouts Across 2019 and 2020 - CAMBRIDGE, Mass.
April 25, 2019	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
April 25, 2019	EX-10.1	Terms and Conditions of Employment between Evelo Biosciences (UK) Limited and Duncan McHale, M.B.B.S., Ph.D., effective as of May 1, 2019 Duncan McHale TERMS AND CONDITIONS OF EMPLOYMENT Employer’s name and address: Evelo Biosciences (UK) Limited of 10 John Street, London, WC1N 2EB (the “Company”) Employee’s name and address: Duncan McHale of [address] (the “Employee”) In terms of the Employment Rights Act 1996 (the “Act”) this document gives details of your terms and conditions of employment with the Company together with other workplace information, as at 1 May 2019.
April 25, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organizati
February 15, 2019	EX-10.12	Master Services Agreement, dated September 1, 2018, between Evelo Biosciences, Inc. and Weatherden Ltd Exhibit Exhibit 10.2
February 15, 2019	10-K	Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES For the Fiscal Year Ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38473 Evelo Bioscie
February 14, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2019 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiz
February 14, 2019	EX-99.1	Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma -- -- Preclinical Studies Have Shown Non-replicatin Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights - First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma - - Preclinical Studies Have Shown Non-replicating Monoclonal Microbials Maintain Activity: EDP1867 in Development - - Initial Clinical Data for EDP1066 in Atopic Dermatitis and Psoriasis Expected in 2Q 2019 - - Initial Clinical Data for EDP1815 in Atopic Dermatitis and Psoriasis Expected in 2H 2019 - - Management to Host Conference Call at 8:30 a.
November 2, 2018	10-Q	EVLO / Evelo Biosciences, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
November 1, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 eveloq38k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2018 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of i
November 1, 2018	EX-99.1	Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights -- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 -- -- Initiation of Investiga Exhibit 99.1 Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights - Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing of First Patient Expected in 4Q18 - - Initiation of Investigator-Sponsored Phase 2a Trial of EDP1503 in Metastatic Melanoma Expected in 4Q18 - CAMBRIDGE, Mass., November 1, 2018 - Evelo Biosciences, In
August 2, 2018	EX-99.1	Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights – Advancing Multiple Product Candidates into Clinical Trials with Dosing of First Patient in Phase 1 Trial of EDP1066 in Psoriasis and Atopic Dermatitis an EX-99.1 Exhibit 99.1 Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights – Advancing Multiple Product Candidates into Clinical Trials with Dosing of First Patient in Phase 1 Trial of EDP1066 in Psoriasis and Atopic Dermatitis and FDA Acceptance of IND for Phase 2a Investigator-Sponsored Trial of EDP1503 in Metastatic Melanoma – – Entered into Research Col
August 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2018 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organi
August 2, 2018	10-Q	EVLO / Evelo Biosciences, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 31, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2018 EVELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38473 46-5594527 (State or other jurisdiction of incorporation or organiza
May 31, 2018	EX-99.1	Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights — Dosing Underway in Phase 1 Clinical Trial of EDP1066 in Psoriasis and Atopic Dermatitis — — IND Accepted by FDA for Phase 2a Investigator-Sponsored Clinic EX-99.1 Exhibit 99.1 Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights — Dosing Underway in Phase 1 Clinical Trial of EDP1066 in Psoriasis and Atopic Dermatitis — — IND Accepted by FDA for Phase 2a Investigator-Sponsored Clinical Trial of EDP1503 in Metastatic Melanoma — — Successfully Completed Initial Public Offering, Raising $85.0 Million in Gross Pro

EVLO / Evelo Biosciences, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)